Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 929

1.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C.

Nature. 2019 Mar;567(7748):399-404. doi: 10.1038/s41586-019-1007-8. Epub 2019 Mar 13.

PMID:
30867590
2.

Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma.

Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, Gorringe KL.

J Pathol. 2019 Mar 6. doi: 10.1002/path.5262. [Epub ahead of print]

PMID:
30843206
3.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX.

Br J Cancer. 2019 Feb 28. doi: 10.1038/s41416-019-0405-x. [Epub ahead of print]

PMID:
30816325
4.

1H NMR characterization of chitin tetrasaccharide in binary H2O:DMSO solution: Evidence for anomeric end-effect propagation.

Li K, Green AR, Dinges MM, Larive CK.

Int J Biol Macromol. 2019 Feb 13;129:744-749. doi: 10.1016/j.ijbiomac.2019.02.062. [Epub ahead of print]

PMID:
30771389
5.

The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts.

Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA.

Mod Pathol. 2019 Feb 13. doi: 10.1038/s41379-019-0209-9. [Epub ahead of print]

PMID:
30760857
6.

'Secret Lists and Sanctions': The Blacklisting of the John Lewis Partnership and the Politics of Pay in 1970s Britain.

Green AR.

20 Century Br Hist. 2019 Feb 7. doi: 10.1093/tcbh/hwy056. [Epub ahead of print]

PMID:
30753661
7.

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.

Savva C, De Souza K, Ali R, Rakha EA, Green AR, Madhusudan S.

Breast Cancer Res Treat. 2019 Feb 12. doi: 10.1007/s10549-018-05113-8. [Epub ahead of print]

PMID:
30746633
8.

Clonal approaches to understanding the impact of mutations on hematologic disease development.

Nangalia J, Mitchell E, Green AR.

Blood. 2019 Feb 6. pii: blood-2018-11-835405. doi: 10.1182/blood-2018-11-835405. [Epub ahead of print]

PMID:
30728143
9.

The prognostic significance of lysosomal protective protein (Cathepsin A) in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, Ellis IO, Green AR, Rakha EA.

Histopathology. 2019 Feb 6. doi: 10.1111/his.13835. [Epub ahead of print]

PMID:
30725481
10.

Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women.

Syed BM, Green AR, Morgan DAL, Ellis IO, Cheung KL.

Cancers (Basel). 2019 Jan 28;11(2). pii: E149. doi: 10.3390/cancers11020149.

11.

The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.

El-Ansari R, Craze ML, Alfarsi L, Soria D, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Jan 22. doi: 10.1007/s10549-018-05111-w. [Epub ahead of print]

PMID:
30671766
12.

Caring for Patients With Multiple Chronic Conditions.

Tinetti ME, Green AR, Ouellet J, Rich MW, Boyd C.

Ann Intern Med. 2019 Jan 22. doi: 10.7326/M18-3269. [Epub ahead of print] No abstract available.

PMID:
30665237
13.

Decision Making for Older Adults With Multiple Chronic Conditions: Executive Summary for the American Geriatrics Society Guiding Principles on the Care of Older Adults With Multimorbidity.

Boyd C, Smith CD, Masoudi FA, Blaum CS, Dodson JA, Green AR, Kelley A, Matlock D, Ouellet J, Rich MW, Schoenborn NL, Tinetti ME.

J Am Geriatr Soc. 2019 Jan 21. doi: 10.1111/jgs.15809. [Epub ahead of print]

PMID:
30663782
14.
15.

Expression of Lamin A/C in early-stage breast cancer and its prognostic value.

Alhudiri IM, Nolan CC, Ellis IO, Elzagheid A, Rakha EA, Green AR, Chapman CJ.

Breast Cancer Res Treat. 2019 Jan 4. doi: 10.1007/s10549-018-05092-w. [Epub ahead of print]

PMID:
30610489
16.

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.

Joseph C, Arshad M, Kurozomi S, Althobiti M, Miligy IM, Al-Izzi S, Toss MS, Goh FQ, Johnston SJ, Martin SG, Ellis IO, Mongan NP, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Apr;174(2):387-399. doi: 10.1007/s10549-018-05085-9. Epub 2018 Dec 15.

PMID:
30554343
17.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Chasampalioti M, Green AR, Ellis IO, Rakha EA, Jackson AM, Spendlove I, Ramage JM.

Breast Cancer Res Treat. 2019 Feb;174(1):93-102. doi: 10.1007/s10549-018-5063-9. Epub 2018 Nov 24.

PMID:
30474779
18.

Glutamate dehydrogenase (GLUD1) expression in breast cancer.

Craze ML, El-Ansari R, Aleskandarany MA, Cheng KW, Alfarsi L, Masisi B, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Feb;174(1):79-91. doi: 10.1007/s10549-018-5060-z. Epub 2018 Nov 23.

PMID:
30470977
19.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, McCaffrey L, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Nov 14. doi: 10.1038/s41379-018-0180-x. [Epub ahead of print]

PMID:
30429518
20.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.

PMID:
30410060
21.

5 S,15 S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1.

Green AR, Freedman C, Tena J, Tourdot BE, Liu B, Holinstat M, Holman TR.

Biochemistry. 2018 Nov 15. doi: 10.1021/acs.biochem.8b00889. [Epub ahead of print]

PMID:
30407793
22.

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.

Johnston SJ, Ahmad D, Aleskandarany MA, Kurozumi S, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA.

BMC Cancer. 2018 Oct 23;18(1):1027. doi: 10.1186/s12885-018-4924-2.

23.

Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.

Alfarsi LH, Elansari R, Toss MS, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Jan;173(1):93-102. doi: 10.1007/s10549-018-4978-5. Epub 2018 Oct 10.

PMID:
30306428
24.

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ.

N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.

PMID:
30304655
25.

Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention.

Ali R, Al-Kawaz A, Toss MS, Green AR, Miligy IM, Mesquita KA, Seedhouse C, Mirza S, Band V, Rakha EA, Madhusudan S.

Cancer Res. 2018 Dec 15;78(24):6818-6827. doi: 10.1158/0008-5472.CAN-18-0633. Epub 2018 Oct 8.

PMID:
30297533
26.

Examining the 'psychopharmacology revolution' (1950-1980) through the advertising of psychoactive drugs in the British Medical Journal.

Green AR, Aronson JK, Haddad PM.

J Psychopharmacol. 2018 Oct;32(10):1056-1066. doi: 10.1177/0269881118796810. Epub 2018 Sep 25.

PMID:
30251594
27.

Population dynamics of normal human blood inferred from somatic mutations.

Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson K, Belmonte M, Osborne RJ, Huntly BJP, Martincorena I, Anderson E, O'Neill L, Stratton MR, Laurenti E, Green AR, Kent DG, Campbell PJ.

Nature. 2018 Sep;561(7724):473-478. doi: 10.1038/s41586-018-0497-0. Epub 2018 Sep 5.

28.

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, McMullin MF, Forsyth C, Kiladjian JJ, Green AR, Harrison CN; United Kingdom Medical Research Council Primary Thrombocythemia-1 Study; United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms Subgroup; French Intergroup of Myeloproliferative Neoplasms; and the Australasian Leukaemia and Lymphoma Group.

J Clin Oncol. 2018 Aug 28:JCO2018788414. doi: 10.1200/JCO.2018.78.8414. [Epub ahead of print]

29.

Assessing the hidden curriculum for the care of patients with limited english proficiency: An instrument development.

Green AR, Rosu C, Kenison T, Nze C.

Educ Health (Abingdon). 2018 Jan-Apr;31(1):17-24. doi: 10.4103/1357-6283.239042.

30.

The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.

Sarwar M, Syed Khaja AS, Aleskandarany M, Karlsson R, Althobiti M, Ødum N, Mongan NP, Dizeyi N, Johnson H, Green AR, Ellis IO, Rakha EA, Persson JL.

Oncogene. 2019 Jan;38(3):375-389. doi: 10.1038/s41388-018-0438-2. Epub 2018 Aug 13.

31.

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.

Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28.

PMID:
30056565
32.

Impact of breast cancer grade discordance on prediction of outcome.

Rakha EA, Aleskandarany MA, Toss MS, Mongan NP, ElSayed ME, Green AR, Ellis IO, Dalton LW.

Histopathology. 2018 Dec;73(6):904-915. doi: 10.1111/his.13709. Epub 2018 Sep 19.

PMID:
29999192
33.

Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.

Shepherd MS, Li J, Wilson NK, Oedekoven CA, Li J, Belmonte M, Fink J, Prick JCM, Pask DC, Hamilton TL, Loeffler D, Rao A, Schröder T, Göttgens B, Green AR, Kent DG.

Blood. 2018 Aug 23;132(8):791-803. doi: 10.1182/blood-2017-12-821066. Epub 2018 Jul 10.

34.

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Nov;31(11):1675-1682. doi: 10.1038/s41379-018-0092-9. Epub 2018 Jun 28.

PMID:
29955149
35.

Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.

Miligy IM, Gorringe KL, Toss MS, Al-Kawaz AA, Simpson P, Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Dec;31(12):1807-1815. doi: 10.1038/s41379-018-0086-7. Epub 2018 Jun 28.

PMID:
29955142
36.

Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.

Althobiti M, Aleskandarany MA, Joseph C, Toss M, Mongan N, Diez-Rodriguez M, Nolan CC, Ashankyty I, Ellis IO, Green AR, Rakha EA.

Histopathology. 2018 Dec;73(6):887-896. doi: 10.1111/his.13695. Epub 2018 Oct 9.

PMID:
29947077
37.

Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients.

Martin SG, Lebot MN, Sukkarn B, Ball G, Green AR, Rakha EA, Ellis IO, Storr SJ.

Oncotarget. 2018 May 25;9(40):25946-25956. doi: 10.18632/oncotarget.25408. eCollection 2018 May 25.

38.

The Use of Figurative Language to Describe Frailty in Older Adults.

Buta B, Leder D, Miller R, Schoenborn NL, Green AR, Varadhan R.

J Frailty Aging. 2018;7(2):127-133. doi: 10.14283/jfa.2018.9.

39.

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.

Kurozumi S, Joseph C, Sonbul S, Gorringe KL, Pigera M, Aleskandarany MA, Diez-Rodriguez M, Nolan CC, Fujii T, Shirabe K, Kuwano H, Storr S, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Aug;170(3):525-533. doi: 10.1007/s10549-018-4777-z. Epub 2018 Apr 9.

PMID:
29633055
40.

Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer.

Alfarsi L, Johnston S, Liu DX, Rakha E, Green AR.

Histopathology. 2018 Oct;73(4):545-558. doi: 10.1111/his.13523. Epub 2018 May 28. Review.

PMID:
29603357
41.

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.

Joseph C, Macnamara O, Craze M, Russell R, Provenzano E, Nolan CC, Diez-Rodriguez M, Sonbul SN, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Mukherjee A.

Br J Cancer. 2018 Apr;118(8):1142-1151. doi: 10.1038/s41416-018-0041-x. Epub 2018 Mar 28.

PMID:
29588513
42.

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.

El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res. 2018 Mar 22;20(1):21. doi: 10.1186/s13058-018-0946-6.

43.

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.

Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, Aneja R, Green AR, Ellis IO, Rakha EA.

Mod Pathol. 2018 Aug;31(8):1226-1236. doi: 10.1038/s41379-018-0040-8. Epub 2018 Mar 20.

PMID:
29559742
44.

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.

El Ansari R, Craze ML, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Br J Cancer. 2018 Apr;118(8):1115-1122. doi: 10.1038/s41416-018-0038-5. Epub 2018 Mar 16.

PMID:
29545595
45.

Breast cancer histologic grading using digital microscopy: concordance and outcome association.

Rakha EA, Aleskandarani M, Toss MS, Green AR, Ball G, Ellis IO, Dalton LW.

J Clin Pathol. 2018 Aug;71(8):680-686. doi: 10.1136/jclinpath-2017-204979. Epub 2018 Mar 13.

PMID:
29535212
46.

Provider Perceptions of the Organization's Cultural Competence Climate and Their Skills and Behaviors Targeting Patient-Centered Care for Socially At-Risk Populations.

Purnell TS, Marshall JK, Olorundare I, Stewart RW, Sisson S, Gibbs B, Feldman LS, Bertram A, Green AR, Cooper LA.

J Health Care Poor Underserved. 2018;29(1):481-496. doi: 10.1353/hpu.2018.0032.

PMID:
29503313
47.

MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling.

Pagano F, Comoglio F, Grinfeld J, Li J, Godfrey A, Baxter J, Silber Y, Green AR.

Leukemia. 2018 Aug;32(8):1826-1830. doi: 10.1038/s41375-018-0053-9. Epub 2018 Feb 27. No abstract available.

48.

Immune Infiltration in Invasive Lobular Breast Cancer.

Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2018 Jul 1;110(7):768-776. doi: 10.1093/jnci/djx268.

49.

Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980).

Green AR, Haddad PM, Aronson JK.

Br J Clin Pharmacol. 2018 Aug;84(8):1668-1685. doi: 10.1111/bcp.13549. Epub 2018 Mar 25. Review.

PMID:
29442380
50.

Thrombopoietin signaling to chromatin elicits rapid and pervasive epigenome remodeling within poised chromatin architectures.

Comoglio F, Park HJ, Schoenfelder S, Barozzi I, Bode D, Fraser P, Green AR.

Genome Res. 2018 Feb 2. pii: gr.227272.117. doi: 10.1101/gr.227272.117. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center